{
    "clinical_study": {
        "@rank": "119363", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "R1: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap in the fasting state\nR2: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap on the high-fat diet\nT1: Single-dose of HCP1007 1g/5mg 4 cap in the fasting state\nT2: Single-dose of HCP1007 1g/5mg 4 cap on the high-fat diet\nR1 -> T2 -> R2 -> T1"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "R2 -> R1 -> T1 -> T2"
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Experimental", 
                "description": "T1 -> R2 -> T2 -> R1"
            }, 
            {
                "arm_group_label": "Group 4", 
                "arm_group_type": "Experimental", 
                "description": "T2 -> T1 -> R1 -> R2"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the pharmacokinetics of omega-3 between\n      rosuvastatin and omega-3 coadministration and HCP1007 in healthy male volunteers."
        }, 
        "brief_title": "A Pilot Study to Evaluate the Pharmacokinetics of Omega-3 Between Rosuvastatin and Omega-3 Coadministration and HCP1007", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult male aged 20 to 55 years\n\n          -  A body mass index between 19 and 27 kg/m2\n\n        Exclusion Criteria:\n\n          -  History of hepatobiliary, renal, gastrointestinal, respiratory, musculoskeletal,\n             endocrinal, hemato-oncologic or cardiovascular disease\n\n          -  SBP < 90 or \u2265 150 mmHg, DBP < 60 or \u226590 mmHg\n\n          -  Use of herbal medicine within 30 days, prescriptive medicine within 14 days, or\n             over-the-counter drug within 7 days\n\n          -  Heavy alcohol consumption (140 g/day)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01929070", 
            "org_study_id": "HM-ROMA-103P"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2", 
                    "Group 3", 
                    "Group 4"
                ], 
                "intervention_name": "HCP1007", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2", 
                    "Group 3", 
                    "Group 4"
                ], 
                "intervention_name": "Omarco and Crestor", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rosuvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HCP1007", 
            "Rosuvastatin", 
            "Omega-3"
        ], 
        "lastchanged_date": "March 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung medical center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Pilot Study to Evaluate the Pharmacokinetics of Omega-3 Between Rosuvastatin and Omega-3 Coadministration and HCP1007 in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "JaeWook Ko, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Cmax_adj of DHA and EPA", 
                "safety_issue": "No", 
                "time_frame": "-24, -22, -20, -19, -18, -16, -14, -12, 0 (predose), 2, 4, 5, 6, 8, 10, 12, 24, 48 h,  72 h (on the high-fat diet only)"
            }, 
            {
                "measure": "AUClast_adj of DHA and EPA", 
                "safety_issue": "No", 
                "time_frame": "-24, -22, -20, -19, -18, -16, -14, -12, 0 (predose), 2, 4, 5, 6, 8, 10, 12, 24, 48 h,  72 h (on the high-fat diet only)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01929070"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax of DHA, EPA", 
                "safety_issue": "No", 
                "time_frame": "-24, -22, -20, -19, -18, -16, -14, -12, 0 (predose), 2, 4, 5, 6, 8, 10, 12, 24, 48 h, 72 h(only on the high fat diet)"
            }, 
            {
                "measure": "AUClast of DHA, EPA", 
                "safety_issue": "No", 
                "time_frame": "-24, -22, -20, -19, -18, -16, -14, -12, 0 (predose), 2, 4, 5, 6, 8, 10, 12, 24, 48 h, 72 h(only on the high fat diet)"
            }, 
            {
                "measure": "AUClast of DHA and EPA", 
                "safety_issue": "No", 
                "time_frame": "-24, -22, -20, -19, -18, -16, -14, -12, 0 (predose), 2, 4, 5, 6, 8, 10, 12, 24, 48 h, 72 h(only on the high fat diet)"
            }, 
            {
                "measure": "tmax of DHA and EPA", 
                "safety_issue": "No", 
                "time_frame": "-24, -22, -20, -19, -18, -16, -14, -12, 0 (predose), 2, 4, 5, 6, 8, 10, 12, 24, 48 h, 72 h(only on the high fat diet)"
            }, 
            {
                "measure": "t1/2 of DHA and EPA", 
                "safety_issue": "No", 
                "time_frame": "-24, -22, -20, -19, -18, -16, -14, -12, 0 (predose), 2, 4, 5, 6, 8, 10, 12, 24, 48 h, 72 h(only on the high fat diet)"
            }, 
            {
                "measure": "AUCinf of DHA and EPA", 
                "safety_issue": "No", 
                "time_frame": "-24, -22, -20, -19, -18, -16, -14, -12, 0 (predose), 2, 4, 5, 6, 8, 10, 12, 24, 48 h, 72 h(only on the high fat diet)"
            }
        ], 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}